Home › Triple-Negative Breast Cancer › South Carolina
Triple-Negative Breast Cancer clinical trials in South Carolina
9 studies for Triple-Negative Breast Cancer are looking for participants at sites in South Carolina.
Cities in South Carolina
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Medical University of South Carolina-Hollings Cancer Center ( Site 0016), Charleston
- St Francis Cancer Center ( Site 0093), Greenville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06966700Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- PRISMA Health/ITOR, Greenville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05983432Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Medical University of South Carolina, Charleston
- St. Francis Cancer Center, Greenville
- Spartanburg Medical Center, Spartanburg
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT05633654A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)
- Medical University of South Carolina Hollings Cancer Center,, Charleston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT07743190A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Charleston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07182149A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- St Francis Cancer Center, Greenville
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT06926868NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients
- Medical University of South Carolina, Charleston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT06845319Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
- Medical University of South Carolina, Charleston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 29, 2026 · NCT04468061A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- Dren Investigational Site, Greenville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jan 7, 2026 · NCT06999187From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.